

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/691,654	10/24/2003	Tomoko Maeda	244295US0CONT	1300
22850	7590 05/03/2005		EXAMINER	
OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C.			AFREMOVA, VERA	
	1940 DUKE STREET ALEXANDRIA, VA 22314		ART UNIT	PAPER NUMBER
	,		1651	

DATE MAILED: 05/03/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	10/691,654	MAEDA ET AL.			
Office Action Summary	Examiner	Art Unit			
	Vera Afremova	1651			
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPL THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a repl If NO period for reply is specified above, the maximum statutory period or  - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailine earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be time y within the statutory minimum of thirty (30) days will apply and will expire SIX (6) MONTHS from the cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. O (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on 10/24/2003.					
2a) ☐ This action is <b>FINAL</b> . 2b) ☐ This	This action is <b>FINAL</b> . 2b) This action is non-final.				
Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims					
4) ⊠ Claim(s) <u>27-41</u> is/are pending in the applicatio 4a) Of the above claim(s) is/are withdray 5) □ Claim(s) is/are allowed. 6) □ Claim(s) is/are rejected. 7) □ Claim(s) is/are objected to. 8) ⊠ Claim(s) <u>27-41</u> are subject to restriction and/or	wn from consideration.				
Application Papers					
9) The specification is objected to by the Examiner.					
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.					
Attachment(s)					
1)	4) Ll Interview Summary ( Paper No(s)/Mail Da	te			
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date		atent Application (PTO-152)			

## **DETAILED ACTION**

Claims 27-41 are pending (preliminary amendment filed 9/07/2004) and subject to restriction requirement.

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 21-25, drawn to a method for producing an osteoclast precursor cell, classified in class 435, subclass 375, for example.
- II. Claim(s) 26, drawn to an osteoclast precursor cell, classified in class 435, subclass372, for example.
- III. Claims 27-36, drawn to a method for producing an osteoclast, classified in class435, subclass 377, for example.
- IV. Claim(s) 37, drawn to an osteoclast, classified in class 424, subclass 93.7, for example.
- V. Claims 38 and 39, drawn to a method for screening an agent for treating metabolic bone disease by using an osteoclast precursor cell, classified in class 435, subclass 4, for example.
- VI. Claim(s) 40, drawn to a method for screening an agent for treating metabolic bone disease by using an osteoclast cell, classified in class 435, subclass 29, for example.
- VII. Claim(s) 41, drawn to an agent for treating metabolic bone disease, classified in class 514, subclass 21, for example.

The inventions are distinct, each from the other because of the following reasons:

The claimed inventions of groups II, IV and VII are directed to three distinct products such as an osteoclast precursor cell, an osteoclast cell and an agent for treating metabolic bone disease.

The claimed inventions of groups I, III, V and VI are directed to distinct methods of making distinct products and using distinct products.

Inventions I and II and Inventions III and IV are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case the cellular products such as an osteoclast precursor cell and an osteoclast cell can be made by different methods are taught by WO 96/07733 (IDS reference; see example 1, pages 28-29, and see example II, page 34).

Inventions I and V and Inventions II and VI are related as product and process of use.

The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the cellular products such as an osteoclast precursor cell and an osteoclast cell can be used in a materially different process for constructing cDNA and protein libraries as taught by WO 96/07733 (IDS reference; see abstract).

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

Art Unit: 1651

Because these inventions are distinct for the reasons given above and the search required for one group is not required for the other group, restriction for examination purposes as indicated is proper.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Vera Afremova whose telephone number is (571) 272-0914. The examiner can normally be reached from Monday to Friday from 9.30 am to 6.00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Wityshyn can be reached at (571) 272-0926.

The fax phone number for the TC 1600 where this application or proceeding is assigned is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Technology center 1600, telephone number is (571) 272-1600.

Vera Afremova

AU 1651

April 29, 2005

VERA AFREMOVA

V. Sprander

PRIMARY EXAMINER